Does Rallies show 13F holders for NERV?

Yes. Rallies tracks hedge fund and 13F ownership data for NERV, including fund names, share counts, latest tracked quarter, and position changes when available.

Is NERV research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NERV. It does not provide personalized investment advice.

NERV (Minerva Neurosciences, Inc) Stock Analysis - Hedge Fund Holdings

Minerva Neurosciences, Inc (NERV) is a publicly traded Healthcare sector company. As of May 21, 2026, NERV trades at $4.67 with a market cap of $220.83M and a P/E ratio of -0.14. NERV moved +15.71% today. Year to date, NERV is +21.20%; over the trailing twelve months it is +264.49%. Its 52-week range spans $1.15 to $12.46. Analyst consensus is buy with an average price target of $10.50. Rallies surfaces NERV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns NERV stock?

Hedge funds tracked by Rallies that own NERV include Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Minerva Neurosciences, Inc.

NERV Key Metrics

Key financial metrics for NERV
Metric	Value
Price	$4.67
Market Cap	$220.83M
P/E Ratio	-0.14
EPS	$-34.67
Dividend Yield	0.00%
52-Week High	$12.46
52-Week Low	$1.15
Volume	40
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-293.42M
Gross Margin	0.00%

Top Hedge Funds Holding NERV

Farallon Capital holds 2.37M shares of NERV, changed +0.00% as of Mar 31, 2026.

Latest NERV News

Minerva Appoints Jim O’Connor as CBO Ahead of Phase 3 Rolupe-ridone Trial — Apr 2, 2026
Minerva Neurosciences Screens First Patient in 380-Patient Phase 3 Trial with Topline Data Due 2H 2027 — Mar 31, 2026
Minerva Neurosciences Finds No Safety Concerns in Roluperidone-Olanzapine Trial, Phase 3 Underway — Mar 25, 2026

Recent NERV Insider Trades

Luthringer Remy sold 3.64K (~$13.69K) on May 2, 2023.
Luthringer Remy sold 23.75K (~$91.45K) on May 1, 2023.
Race Geoff sold 22.08K (~$85.02K) on May 1, 2023.

NERV Analyst Consensus

2 analysts cover NERV: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.50.

Common questions about NERV

Who owns NERV stock?: Hedge funds tracked by Rallies that own NERV include Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Minerva Neurosciences, Inc.
Does Rallies show 13F holders for NERV?: Yes. Rallies tracks hedge fund and 13F ownership data for NERV, including fund names, share counts, latest tracked quarter, and position changes when available.
Is NERV research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NERV. It does not provide personalized investment advice.